Kornimate/medical-research-clean huggingface dataset:
quadriceps muscle plasticity in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: our primary aim is to determine whether and how muscle architecture of the quadriceps muscles in cerebral palsy (cp) adapts to two separate training programs: traditional strength training (st) vs. velocity-enhanced training (vt). for the st group, we hypothesize that muscle size will increase in conjunction with strength. for the vt group, in addition to the above, we hypothesize that fiber length will increase with measures of muscle power. we also hypothesize that walking velocity will improve in both groups but that knee motion and step length will improve only with vt.

cerebral palsy (cp) is the most common physical disability originating in childhood, occurring in 2-3 per 1,000 live births. although the primary deficit in cp is injury to the brain, secondary impairments affecting muscle function such as weakness, contractures, and spasticity are often far more debilitating and lead to worsening disability throughout the lifespan. some have suggested that these muscle changes in cp may be irreversible; however, it is now known that muscles are one of the most 'plastic' tissues in the body. in fact, recent evidence suggests that gross muscle hypertrophy and architectural changes within muscle fibers can occur as early as 3-5 weeks after resistance training in healthy adults. it is also unknown how effectively muscles in cp can adapt to training stimuli that target specific muscle architectural parameters, such as fascicle length and cross-sectional area. these parameters have been observed to be decreased in cp, suggesting loss of sarcomeres in-series (fiber shortening) and in-parallel (muscle atrophy). we propose here that specific training-induced muscle architectural adaptations can occur in cp, leading to improved motor function.

Eligibility criteria:
inclusion criteria: * diagnosis of cerebral palsy * gross motor function classification system levels i, ii, or iii * ages 7 to 17 exclusion criteria: * orthopedic or neurosurgery within the past year * botulinum toxin injections within the 4 months prior to the study

Keywords: cerebral palsy muscle strength muscle architecture ultrasound rehabilitation rectus femoris quadriceps muscle
gut microbiota and multiple sclerosis

Conditions: Multiple Sclerosis

Summary: gut microbiota and multiple sclerosis multiple sclerosis is a pro-inflammatory demyelinating disease of the central nervous system.

multiple sclerosis is a pro-inflammatory demyelinating disease of the central nervous system. the etiology of ms is complex and poorly understood. both genetic and environmental factors play a role and recent evidence suggests that gut microbiota is one of the key environmental factors. gut microbiota is increasingly being seen an important environmental risk factor for multiple sclerosis, and strategies to correct an imbalance in intestinal flora.the first study, "multiple sclerosis patients have a distinct gut microbiota compared to healthy controls," published in scientific reports, found that people with relapsing-remitting ms have altered fecal microbiota and may have microbial dysbiosis. people with ms had reduced levels of a protein called aryl hydrocarbon receptor circulating in their blood.aryl hydrocarbon receptor is involved in many biological processes, including inflammation. the researchers found that gut microbiota play a role in turning tryptophan, and amino acid found in food, into aryl hydrocarbon receptor agonists, which act on cells of the nervous system called astrocytes and limit inflammation of the central nervous system. low levels of aryl hydrocarbon receptor in multiple sclerosis patients may explain how microbial dysbiosis could be causing the condition.increased constipation and fecal incontinence and increased gut permeability in multiple sclerosis patients, and increased occurrence of inflammatory bowel diseases in ms patients and their families suggest an important gut-central nevus system connection.interestingly, gut bacteria can also influence the blood brain barrier integrity. these studiesimplicate that gut microbiota may potentially be operational in predisposition to or modification of the disease course of multiple sclerosis.

Eligibility criteria:
inclusion criteria: * the study will included 40 cases of ms according to diagnostic criteria of multiple sclerosis they classified into two types of multiple sclerosis ,relapsing-remitting ms (group 1), and primary progressive ms, secondary progressive ms, and progressive relapsing ms (group 2). each patient was submitted to the following: expanded disability status scale score between 1 and 6 and functional system score. demographic and clinical data (age, sex, age of onset, severity of disease, clinical symptoms and signs, types of treatment, duration of treatment, number of attacks). exclusion criteria: * the general exclusion criteria included prior surgeries, any patients or controls currently taking antibiotics or probiotic supplements,or having a known history of disease with an disease such, rheumatoid arthritis,type-1-diabetes, and ibd, were also excluded from the study.microbial dna was extracted from fecal material of each sample.
randomized controlled trial to evaluate the efficacy of the salfoam 3% method compared to the conventional polidocanol foam method (tessari method) for treating lower limb varicose veins

Conditions: Varicose Veins

Summary: this clinical trial aims to assess the efficacy and safety of the salfoam 3% method, which involves saline wash, polidocanol 3% foam injection, and extrinsic compression using lidstop®, in comparison with the conventional tessari method for the treatment of lower limb varicose veins. the primary objective is to determine whether the salfoam 3% method results in better or equivalent vein occlusion rates and fewer adverse effects, such as hyperpigmentation, compared to the standard treatment.

chronic venous disease (cvd) is prevalent in approximately 38% of the adult population in brazil, posing significant public health challenges due to its potential complications, including ulcerations and reduced quality of life. the salfoam 3% method is a novel approach that combines saline wash prior to polidocanol 3% foam sclerotherapy and extrinsic compression with lidstop®, aiming to improve outcomes by reducing adverse effects such as hyperpigmentation and enhancing patient quality of life. this randomized controlled trial will compare the efficacy, safety, and quality of life outcomes of patients treated with the salfoam 3% method versus those treated with the conventional tessari method for lower limb varicose veins.

Eligibility criteria:
inclusion criteria: * adults aged 18 years or older with clinically confirmed varicose veins in the lower limbs by ultrasonography. * all fitzpatrick skin types (i-vi). * ability to provide written informed consent. exclusion criteria: * pregnancy or breastfeeding. * known allergy or adverse reaction to polidocanol or similar agents. * active infection in the area of treatment. * immunosuppressed patients. * severe coagulopathies or a history of recent deep vein thrombosis or pulmonary embolism. * diagnosis of patent foramen ovale. * ceap classification vi (active venous ulcers). * use of medications that may interfere with the study outcomes. * inability to comply with the study protocol or refusal to participate.

Keywords: chronic venous disease varicose veins polidocanol foam sclerotherapy salfoam 3% tessari method vein occlusion hyperpigmentation
playfit pilot: encouraging social physical play in the community

Conditions: Overweight and Obesity

Summary: the investigator is pilot testing the feasibility and impact of a low-cost intervention that uses existing gymnasiums, and therefore has the potential to be replicated across the united states. the intervention, playfit, is designed for adults aged 21-50. playfit has five key components, intended to overcome the major barriers to physical activity. first, it will assist people in finding others to play with, using the pick-up model of designating times to play and making those times known in the community. second, it will overcome a lack of confidence in physical activity by including games of lower intensity for relatively unfit adults, then building up to moderate and vigorous games. third, it will require team members of varying ages and genders to encourage intergenerational play. fourth, it will use modified equipment (e.g., softer, lighter balls) and smaller game space to require less running, so that even relatively unfit people can feel confident participating. fifth, it will be designed to be led by community volunteers, which will increase its disseminability. aim - understand the optimum design for playfit. to meet this aim, the investigators will come up with a list of games to play and pilot the games at a gymnasium. the investigators will observe the participants playing the games and have them complete a brief survey.


Eligibility criteria:
inclusion criteria: * age 21-50 * fluently read and speak english * current member of hershey medical center's university fitness center or willing to become a member * currently exercises \< 150 minutes per week exclusion criteria: * has been told by a doctor they a heart condition and should only do exercise recommended by a doctor * currently pregnant or planning to become pregnant in the next 6 months * planning to move out of the area in the next 6 months * has pain in chest, neck, jaw, or arms at rest, during daily activities of living * has experienced a forceful or rapid heart rate * has experience unreasonable breathlessness * has experienced dizziness fainting or blackouts * has experienced ankle swelling * has burning or cramping sensation in lower legs when walking short distances * has been told by a health professional not to exercise or exercise only when supervised by a professional * has been diagnosed with diabetes * has been told by a doctor, nurse or health professional that they have (1) weak or failing kidneys, (2) a heart attack/ myocardial infarction, (3) angina or coronary heart disease, (4) a stroke, or (5) any other kind of heart condition or heart disease - e.g. heart valve problem/aortic regurgitation (do not include heart murmur)
pharmaceutical care of patients with impaired mobility in a model-region of decreasing supply of medical services

Conditions: Diabetes

Summary: design and procedure: the design is a randomised controlled multi-centre pilot study. 18 community pharmacies located in mecklenburg-western pomerania, germany, were randomised to either a control or an intervention group. these pharmacies recruited eligible patients out of their clientele and invited them to take part in the study. participants were visited at home by the pharmacist and home-based medication reviews were conducted. the survey form has been developed by the research team and comprised amongst others items to adherence, adverse effects, drug intake, storage and quality of life. thereafter all data were analysed by the pharmacist with a newly developed document called "analysis guide" aiming at the detection of drug related problems. pharmacists of the intervention group discussed the results with the family doctor of the patients and the patients and tried to solve the drug related problems. this procedure was not undertaken in the control group. six months later a second medication review was carried out in both groups. study hypothesis: pharmaceutical care reduces the overall number of drug-related problems of elderly patients with diabetes and impairments in mobility. aim: the purpose of this study is to show that pharmaceutical care reduces the overall number of drug-related problems of elderly diabetes-patients with impairments in mobility and leads to both an improved health status and an improved quality of life.


Eligibility criteria:
inclusion criteria: * impairment in mobility * age of 65 years or older * four or more long-term medications * diabetes * at least one of the following co-morbidities: hypertension, obesity, hypercholesteremia, hyperlipidemia, coronary heart disease, cardiac insufficiency, angina pectoris, peripheral vascular disease exclusion criteria: * patient lives in a home for the aged or a residential care home for the elderly * terminal renal failure, dialysis * moderately or severe dementia or other severe cognitive impairments * terminal diseases (e.g. cancer) * nursing service if the medicine is directly administered to the patient

Keywords: pharmaceutical care drug-related problems elderly pharmaceutical care of elderly patients with diabetes
the change of urinary angiotensinogen excretion after valsartan treatment in patients with persistent proteinuria

Conditions: Chronic Kidney Disease; Proteinuria

Summary: this study is a multicenter, prospective, interventional study. it does not have a control group. all participants will receive 160 mg valsartan for 8 weeks. among them, the patients with persistent proteinuria (defined as proteinuria more than 1 g/g after 8 weeks treatment of valsartan) will receive 320 mg valsartan for further 16 weeks. participants who did not receive any acei or arb previously will have a titration period for 4 weeks (80 mg for 4 weeks, 160 mg for 4 weeks, and then 320 mg for 16 weeks). the investigators will evaluate the change of urinary angiotensinogen excretion between at baseline, at 8 weeks, and 24 weeks.


Eligibility criteria:
inclusion criteria: * chronic kidney disease patients with * proteinuria of 1 - 10 g/day, * stable and controlled blood pressure (100/60 mmhg - 160/100 mmhg), * stable renal function with gfr ≥ 30 ml/min/ m2, * diabetes or non-diabetes exclusion criteria: * uncontrolled diabetes (defined as hba1c \> 9.0%) * immunosuppressive treatment within 6 months * intractable edema * hyperkalemia (\>5.5 meq/l) or hypokalemia (\< 3.5 meq/l)

Keywords: proteinuria chronic kidney disease renin-angiotensin system angiotensinogen
dorsal root ganglion stimulation as treatment for post-surgical groin pain

Conditions: Post Surgical Groin Pain

Summary: 25-smi-2014 is a post market observational, questionnaire based study to assess the effectiveness of the axium neurostimulator as a treatment for chronic post surgical groin pain. within is also a nested feasibility study to assess the clinical utility of a quantitive sensory testing (qst) protocol in the management of the described study group.


Eligibility criteria:
main study inclusion criteria: 1. male 2. age between \>18 and \<65 years 3. unilateral post surgical groin pain for \>6 months 4. pain localized to the region defined by the anterior superior iliac spine (asis), the pubic tubercle, and the groin-gluteal-greater trochanter triangles (3g) point, 5. pain has no surgical indication 6. subjects meet the criteria for scs implantation as set out in the dutch neuromodulation society guideline 7. pain characterized by neuropathy and/or allodynia 8. average daily baseline pain intensity baseline vas greater than or equal to 50 mm on a 100mm vas scale 9. patient willing and able to give informed consent and to participate in observational study exclusion criteria: 1. inability to speak/read dutch 2. bilateral and/or recurrent hernia. 3. radiofrequency or injection therapy at or close to a target drg in the 90 days prior to enrolment 4. current illicit drug use and/or alcohol dependence 5. active infection, or conditions or indwelling devices that pose an increased risk of infection 6. active implantable device including implantable cardiac defibrillator, pacemaker, spinal cord stimulator or intrathecal drug pump 7. participation in another clinical study during the study period. 8. any other disorder, condition, or circumstance that, in the opinion of the principal investigator, represents a risk to successful completion of all study activities. additional criteria for nested feasibility study additional inclusion criteria 1. participation in the observational study 2. sign off for sub-study on patient informed consent additional exclusion criteria 1. for sub-study participation only: pain conditions \[aside from the post surgical groin pain to be treated\], extensive scar tissue, skin conditions, or sensorimotor abnormalities in the areas for qst assessments: the painful groin, the contralateral groin, the ipsilateral arm, and the contralateral hand
educational intervention to adherence of patients treated by capecitabine +/- lapatinib

Conditions: Metastatic Breast Cancer; Colorectal Cancer

Summary: the purpose of this study is to evaluate the efficacy of the implementation of an educational program on adherence to capecitabine alone or in combination to lapatinib.

200 subjects who meet the inclusion/exclusion criteria treated by capecitabine +/- lapatinib, will be enrolled into the study. adherence to treatment of all subjects will be assessed during a first adherence evaluation period of 3 cycles in order to identify patients who need educational intervention(non adherent patients). only nonadherent patients (adherence rate \< 80%) will receive an education intervention. during the educational program, the efficacy of the implementation of an educational program on adherence to capecitabine alone or in combination to lapatinib will be evaluated for the 6 subsequent cycles.

Eligibility criteria:
inclusion criteria: * age\> 18 years * histologically confirmed breast cancer or colorectal cancer * patient starting oral treatment : capecitabine alone or in combination with lapatinib (can be included before the first cycle or during the first 2 cycles). * volunteer to participate in the study. * ambulatory treated patient * able to read, write and understand french. * subject who accept to use mems monitors to automatically compile their drug dosing histories * written informed consent exclusion criteria: * more than 3 metastatic chemotherapies * any severe concomitant condition which makes it undesirable for the patient to participate in the study or which would jeopardize adherence with trial protocol

Keywords: educational intervention adherence capecitabine lapatinib
northern alberta psychosocial telecare (napt) screening for hnc patients

Conditions: Cancer Distress

Summary: this is a randomized controlled trial comparing a web-based psychosocial screening application to usual care in a cohort of surgically-treated head and neck cancer patients to determine its efficacy in monitoring depression and distress, and prompting necessary psychiatry/psychology referrals. in addition, treatment adherence, rehabilitation and return to work, primary care utilization, and survival will be monitored.

this is a randomized controlled trial comparing a web-based psychosocial screening application to usual care in a cohort of surgically-treated head and neck cancer patients. this study will utilize a web-based application available on desktop or laptop computers, and smartphones. the application involves monitoring using the nccn distress thermometer score, the quick inventory of depressive symptomatology-self report (qids-sr) score, and the head and neck research network (hnrn-33), a patient-reported, validated functional outcomes score. these assessments will be completed at baseline, 2 weeks postoperatively, and monthly thereafter until 12 months. patients will have the option of filling out questionnaires more frequently if desired. this web-based application, the napt app, will allow patients to alert the treatment team of their current state of mood or distress. automatic alerts will be sent to the team if a distress score of \ /=11, or suicidal ideation are expressed in the application. the study duration will be 12 months with a primary endpoint of 6 months. our primary outcome will be nccn distress thermometer score at 6 months, with secondary outcomes of the qids and hnrn-33 functional scores at 6 and 12 months. additional outcomes assessed will pertain to completion of adjuvant therapy, weight maintenance, rehabilitation and return to work, and survival. health services delivery outcomes, such as primary care visits, emergency department visits, hospitalizations, and narcotic use will also be evaluated.

Eligibility criteria:
inclusion criteria: * 18 years * new (non-recurrent) head and neck cancer * primary surgical treatment exclusion criteria: * \<18 years * recurrent head and neck cancer * previous chemotherapy or radiation therapy * history of psychiatric or psychologic illness * history of previous cancers or cancer distress
study to create potential cell-based therapies to treat human disease and disability

Conditions: Metabolic Diseases; Infertility

Summary: this is a research study in which your cells will be used for somatic cell nuclear transfer (scnt), and/or genetic reprogramming research which may result in the production of stem cell lines. this study does not provide treatment.

it is thought that studies of genetic reprogramming and scnt using human cells have the potential to give us new basic knowledge about human development. current work will focus on developing this basic knowledge. in the future, human embryonic stem cell lines (hesc) derived from genetic reprogramming and scnt may also have the potential to develop into cell types that are useful for cell-based therapies to treat human disease and disability.

Eligibility criteria:
inclusion criteria:1. donors with a degenerative disease phenotype or genetic disorders such as type i diabetes, heart disease, or infertility (azoospermia and premature ovarian failure) exclusion criteria:1. unable to read or understand english. 2. unable to provide skin biopsy sample due to skin condition in the underarm area.
a study of mabthera (rituximab) in primary central nervous system lymphoma.

Conditions: Lymphoma

Summary: this study will evaluate the efficacy and safety of mabthera plus high dose methotrexate plus high dose cytarabine in patients with central nervous system non-hodgkin's lymphoma. eligible patients will receive a treatment regimen consisting of mabthera (750mg/m2 iv) plus methotrexate (8g/m2 iv) given at intervals up to week 22, plus cytarabine (2g/m2 iv) at week 11 and week 22. the anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, 18-80 years of age; * histological diagnosis of primary central nervous system lymphoma; * b-cell proliferation verified by positive staining for cd20; * \>=1 measurable lesion. exclusion criteria: * prior chemotherapy, other than corticosteroids, \>=6 weeks before and after diagnosis or surgery; * history of prior cranial irradiation; * evidence of plurisystemic non-hodgkin's lymphoma; * other active malignant disease (other than basal cell or squamous cell cancer of skin,or cancer in situ of cervix; * uncontrolled active infection.